Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry
about
Everolimus-eluting stents improve vascular response in a diabetic animal model.Paclitaxel-eluting versus sirolimus-eluting stents in diabetes mellitus: a report from the National Heart, Lung, and Blood Institute Dynamic Registry.Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary interventionRevascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting.Relationship between red blood cell distribution width and intermediate-term mortality in elderly patients after percutaneous coronary interventionOral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview.Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational studyDifferences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease.Coronary artery disease and diabetes mellitus.Effects of daily glucose fluctuations on the healing response to everolimus-eluting stent implantation as assessed using continuous glucose monitoring and optical coherence tomography.Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry.Safety of temporary and permanent suspension of antiplatelet therapy after drug eluting stent implantation in contemporary "real-world" practiceAccelerating degradation rate of pure iron by zinc ion implantation.Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularizationCoronary stent thrombosis in patients with chronic renal insufficiency.Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era.Use of drug-eluting stents in patients with coronary artery disease and renal insufficiency.Benefits of and safety concerns associated with drug-eluting coronary stents.Current concepts on coronary revascularization in diabetic patients.Variability of clopidogrel response in patients with type 2 diabetes mellitus.Stent thrombosis in patients with chronic kidney disease.Antiplatelet therapy in the management of cardiovascular disease in patients with CKD: what is the evidence?Clinical impact of genetically determined platelet reactivity.Percutaneous versus surgical interventions for coronary artery disease in those with diabetes mellitus.Assessing post-treatment platelet reactivity: a focus on patient selection and setting.Coronary artery bypass grafting versus drug-eluting stents in patients with severe coronary artery disease and diabetes mellitus: systematic review and meta-analysis.Target lesion calcification and risk of adverse outcomes in patients with drug-eluting stents. A meta-analysis.Prognostic Implications of Chronic Kidney Disease on Patients Presenting with ST-Segment Elevation Myocardial Infarction with versus without Stent Thrombosis.Second-generation versus first-generation drug-eluting stents in patients with and without diabetes mellitus: pooled analysis from the RESET and NEXT trials.The comparative safety of bare-metal and drug-eluting intracoronary stents.Incidence and prognosis of stent thrombosis following percutaneous coronary intervention in Middle Eastern patients: The First Jordanian Percutaneous Coronary Intervention Registry (JoPCR1).PRotective Effect on the coronary microcirculation of patients with DIabetes by Clopidogrel or Ticagrelor (PREDICT): study rationale and design. A randomized multicenter clinical trial using intracoronary multimodal physiology.High glycemic stenting menu.Which DES for diabetics? Round 1: A draw. Round 2: Everolimus leading?Clustering of acute and subacute stent thrombosis related to the introduction of generic clopidogrel.Two-year clinical outcomes with paclitaxel-eluting coronary stents in patients with chronic total occlusions: analysis from the TAXUS ARRIVE program.Macrovascular Complications in Patients with Diabetes and Prediabetes.Randomized trials of PCIs versus CABG surgery: why coronary stenting should remain the first choice of revascularization in non-diabetic patients and why the controversy is still present in diabetics.Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents.
P2860
Q34076128-04163577-C1C5-4A46-BB8C-F4DE2DA5B5A4Q34162064-A3706B13-E9BE-4F39-8B8B-2CF48ADFAC3BQ34726838-BD83B097-7FA4-4704-A8A9-E03E85D39309Q34793647-2B8521AE-4EE2-4331-B76B-67C85E90BB2FQ35019663-CA27B406-B6E6-4947-A4DB-94E820C34700Q35141772-0F6F74A3-8221-4272-AC92-63319C04307AQ35677083-BEC8180C-F4F5-4638-9994-54146C591AC4Q35883494-748DF03F-4AFE-4020-873E-5B9870D5B98AQ36355228-AA303032-AD24-414C-8E6C-0952C4244FAFQ36923284-6287AD70-E8C6-42DF-8105-9C72CE17DE15Q37089062-182A37E6-8C66-4306-8499-DD801D2F6B3BQ37134004-1D4741E8-8DB0-4195-AA53-B6DEDC92A8D0Q37137837-2083BF65-328E-4F36-A71B-1A3DA40D1ECCQ37167506-B6569702-0767-43F5-A3D7-B3F1A4334E56Q37582058-E84C072B-D874-44E2-A23E-FA5FB1A47E6EQ37588002-27F71BC3-E3B9-4EF7-B794-D101CAEDE029Q37684624-2B8498F6-5734-4B26-844B-07D35B2A6910Q37707419-86066644-760D-4927-B737-B9072CCA5F98Q37926750-52B27079-1BF4-46A1-994B-5D788F7033C5Q37936014-27880F42-7BAF-4A56-BE76-95C9B1E5A3BDQ38014979-AA195B4B-A22E-4A2E-87AC-C89401186CC5Q38048245-FBA09FB4-C368-4C21-98DE-62AA8B543554Q38059616-602630A4-5F3A-4F28-8F9A-FDF349CC45F1Q38068350-05A5BE0C-F89A-47E7-A0D1-CD8ABA5FF83FQ38132923-0D62778C-65DB-4EE0-9402-9B0DA00637D7Q38217328-CF291EB5-8C23-4FFE-BC3D-D945271C3A46Q38538723-4B61C2C3-CB9A-4C43-AD4A-BA46A50ADEB1Q38726862-588A569F-086E-4ADC-8345-090E22EB1CE1Q38985165-064C6E97-1D81-4DAD-A650-8013B169C675Q39840291-1FF1B86C-E2F7-4540-8FB6-2A280EFAED65Q39963040-F7453D4E-424E-4C47-B4A0-D693988589A8Q42254531-E3B87407-48CA-4116-B752-64118BB71D70Q42792267-80EE705E-A760-433A-9AF7-E7D1BD55D446Q43005701-76800E66-F036-43A8-A5F8-5643F6B1095DQ43911948-0D90B4C0-E0E4-4248-B970-0F29C945FD34Q45366439-17B469A2-9A90-4CA2-BB57-471F79974F1CQ46241567-0B5CC92D-F174-4A73-AEA6-D0324C9888D8Q46456558-1BC16B65-CD6F-472C-884D-6FB93A0A0B3EQ46761762-58BBA35B-FACD-4FBB-A8BF-2D5A643D60B5Q46944476-D8DF644E-4498-432B-A0F3-5B50A170BF60
P2860
Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Risk factors for stent thrombo ...... ASTENT Matched-Cohort Registry
@ast
Risk factors for stent thrombo ...... ASTENT Matched-Cohort Registry
@en
Risk factors for stent thrombo ...... ASTENT Matched-Cohort Registry
@nl
type
label
Risk factors for stent thrombo ...... ASTENT Matched-Cohort Registry
@ast
Risk factors for stent thrombo ...... ASTENT Matched-Cohort Registry
@en
Risk factors for stent thrombo ...... ASTENT Matched-Cohort Registry
@nl
prefLabel
Risk factors for stent thrombo ...... ASTENT Matched-Cohort Registry
@ast
Risk factors for stent thrombo ...... ASTENT Matched-Cohort Registry
@en
Risk factors for stent thrombo ...... ASTENT Matched-Cohort Registry
@nl
P2093
P3181
P1476
Risk factors for stent thrombo ...... ASTENT Matched-Cohort Registry
@en
P2093
Alison Foote
Gérald Vanzetto
Hélène Eltchaninoff
Jacques Machecourt
Jean Louis Bonnet
Jean Louis Quesada
Jean Marc Lablanche
Jean Marie Fauvel
Nicolas Danchin
Stephanie Marliere
P3181
P356
10.1016/J.JACC.2007.04.051
P407
P577
2007-08-07T00:00:00Z